Renal cell carcinoma

31 trials 10 recruiting MedDRA PT
31 Registered trials
10 Recruiting
17 Unique sponsors
29 Unique IMPs
29 Commercial trials
Drug classes (ATC)
— ATC code not specified 15
L Oncology (ATC L) 14
N Neurology/Psychiatry (ATC N) 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 11 substances
Kinase inhibitor 6 substances
Checkpoint inhibitor (PD-1) 2 substances
Monoclonal antibody (immune) 2 substances
Checkpoint inhibitor (CTLA-4) 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
PARP inhibitor 1 substance
Taxane 1 substance
Antimetabolite 1 substance
RAF/BRAF inhibitor 1 substance
BCL-2 inhibitor 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Phase III: 7 Phase II: 4 Phase I/II: 5 Phase I: 7 Phase I (Other): 6 Phase I (First in Human): 2

Filter these 31 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 31 trials

Phase III

7 trials
  • Aveo Pharmaceuticals Inc. Commercial
    NIVOLUMAB
    2024-514570-43-00 8 countries 2022 n=169
    Ended
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    IPILIMUMAB; NIVOLUMAB
    2023-508264-29-00 8 countries 2019 n=254
    Ended
  • F. Hoffmann-La Roche AG Commercial
    ALECTINIB; ALECTINIB HYDROCHLORIDE; ATEZOLIZUMAB; CABOZANTINIB; COBIMETINIB; NIRAPARIB; PACLITAXEL; PEMETREXED; SUNITINIB; VEMURAFENIB; VENETOCLAX
    2023-506184-34-00 11 countries 2019 n=104 Orphan
    Ended
  • F. Hoffmann-La Roche AG Commercial
    ATEZOLIZUMAB; CABOZANTINIB
    2024-517785-42-00 2 countries 2020 n=64
    Ended
  • Merck Sharp & Dohme LLC Commercial
    N-(4-FLUOROPHENYL)-N-(4-((7-METHOXY-6-(METHYLCARBAMOYL)QUINOLIN-4- YL)OXY)PHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE
    2024-516993-31-00 9 countries 2026 n=311
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    CABOZANTINIB; N-(4-FLUOROPHENYL)-N-(4-((7-METHOXY-6-(METHYLCARBAMOYL)QUINOLIN-4- YL)OXY)PHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE
    2024-517136-21-00 12 countries 2025 n=398
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    BELZUTIFAN; LENVATINIB
    2025-524160-38-00 10 countries 2026 n=37
    Recruiting

Phase II

4 trials
  • Ipsen Pharma Commercial
    CABOZANTINIB
    2024-514479-16-00 2 countries 2019 n=6
    Ended
  • Merck Sharp & Dohme LLC Commercial
    MRNA-4157; PEMBROLIZUMAB
    2023-505177-32-00 5 countries 2024 n=101
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB
    2023-506017-22-00 2 countries 2024 n=44
    Ended
  • Assistance Publique Hopitaux De Paris Academic
    IMP not specified
    2024-514085-39-00 1 country 2026 n=60
    Recruiting

Phase I/II

5 trials
  • Bristol Myers Squibb International Corporation Commercial
    NIVOLUMAB
    2023-503554-12-00 5 countries 2019 n=96
    Ended
  • Bristol Myers Squibb International Corporation Commercial
    NIVOLUMAB; NIVOLUMAB, RELATLIMAB; RELATLIMAB
    2023-508067-70-00 9 countries 2015 n=1,003
    Ended
  • Merck Sharp & Dohme LLC Commercial
    BELZUTIFAN; LENVATINIB; PEMBROLIZUMAB; PEMBROLIZUMAB, FAVEZELIMAB; PEMBROLIZUMAB, QUAVONLIMAB; PEMBROLIZUMAB, VIBOSTOLIMAB
    2023-506838-68-00 5 countries 2020 n=62
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    BELZUTIFAN; LENVATINIB; MK-4830; PEMBROLIZUMAB; PEMBROLIZUMAB, FAVEZELIMAB; PEMBROLIZUMAB, QUAVONLIMAB
    2023-506839-15-00 5 countries 2020 n=68
    Ended
  • Merck Sharp & Dohme LLC Commercial
    BELZUTIFAN; N-(4-FLUOROPHENYL)-N-(4-((7-METHOXY-6-(METHYLCARBAMOYL)QUINOLIN-4- YL)OXY)PHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE
    2024-516437-12-00 3 countries 2025 n=33
    Recruiting

Phase I

7 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-509335-60-00 4 countries 2023 n=177
    Recruiting
  • Beigene Ltd. Commercial
    IMP not specified
    2023-503996-38-00 1 country 2025 n=60
    Ended
  • Beigene Ltd. Commercial
    IMP not specified
    2023-505322-34-00 1 country 2024 n=45
    Ended
  • Exelixis Inc. Commercial
    IMP not specified
    2024-515617-18-00 5 countries 2022 n=140
    Ended
  • Kura Oncology Inc. Commercial
    IMP not specified
    2024-513285-19-00 4 countries 2025 n=66
    Recruiting
  • Molecure S.A. Commercial
    IMP not specified
    2024-510836-31-00 1 country 2023 n=40
    Recruiting
  • Novartis Pharma AG Academic
    IMP not specified
    2022-500540-38-00 5 countries 2023 n=88
    Ended

Phase I (Other)

6 trials
  • AstraZeneca AB Commercial
    LENVATINIB; VOLRUSTOMIG
    2023-509604-15-00 2 countries 2021 n=93
    Ended
  • Disruptive Pharma AB Commercial
    IMP not specified
    2024-514496-18-00 1 country n=20
    Not authorised
  • Disruptive Pharma AB Commercial
    IMP not specified
    2024-514496-18-01 1 country 2025 n=12
    Ended
  • Exelixis Inc. Commercial
    IMP not specified
    2024-516477-73-00 2 countries 2018 n=320
    Ended
  • Molecure S.A. Commercial
    IMP not specified
    2024-513006-61-00 1 country 2023 n=30
    Recruiting
  • Toray Industries Inc. Commercial
    IMP not specified
    2024-513915-28-00 1 country 2019 n=32
    Ended

Phase I (First in Human)

2 trials
  • Beigene Ltd. Commercial
    LBL-007; SURZEBICLIMAB; TISLELIZUMAB
    2022-500694-14-00 4 countries 2023 n=48
    Ended
  • Pathios Therapeutics Limited Commercial
    NIVOLUMAB; PTT-4256
    2025-522944-41-00 2 countries n=95
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Merck Sharp & Dohme LLC Commercial 8 Phase II, Phase III, Phase I/II 5
Beigene Ltd. Commercial 3 Phase I, Phase I (First in Human) 0
Exelixis Inc. Commercial 2 Phase I, Phase I (Other) 0
Molecure S.A. Commercial 2 Phase I, Phase I (Other) 2
Disruptive Pharma AB Commercial 2 Phase I (Other) 0
F. Hoffmann-La Roche AG Commercial 2 Phase III 0
Bristol Myers Squibb International Corporation Commercial 2 Phase I/II 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I 1
Kura Oncology Inc. Commercial 1 Phase I 1
AstraZeneca AB Commercial 1 Phase I (Other) 0
Toray Industries Inc. Commercial 1 Phase I (Other) 0
Ipsen Pharma Commercial 1 Phase II 0
Aveo Pharmaceuticals Inc. Commercial 1 Phase III 0
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase III 0
Pathios Therapeutics Limited Commercial 1 Phase I (First in Human) 0
Novartis Pharma AG Academic 1 Phase I 0
Assistance Publique Hopitaux De Paris Academic 1 Phase II 1
New trials by year
2019
5
2020
3
2021
1
2022
2
2023
5
2024
3
2025
5
2026
3
← All indication landscapes